MediVet (MLA is divesting)

ABN: 30 096 048 912
Unit 4B, 128-130 Frances St, Lidcombe, NSW, 2141, Australia
PO BOX 445, Lidcombe, NSW, 2141
T +612 9466 5300 F +612 9922 7165
www.medaust.com
MLA finalises sale of MediVet
 MLA transfers its interests in MediVet Biologics in management buyout
 Company now solely focussed on the growth and development of Human Healthcare business
Sydney, 22nd December 2015: Human and Animal Healthcare company Medical Australia Limited (“MLA”, the “Company”)
wishes to announce that the Company has finalised the sale of its 60.5% interest in MediVet Biologics (“MediVet”), its US
based Animal Healthcare business. Following an extensive marketing program the Company has reached agreement to sell its
interest in MediVet to Mr Jeremy Delk, currently CEO of Medivet Biologics.
MLA will receive $US52,000 upon settlement which is anticipated to occur prior to the end of the calendar year. A further
payment of up to $US2,000,000 is contingent on the future sales of assets in MediVet Biologics.
As previously advised to shareholders, MLA has over the past two years made a significant investment of both financial and
human resources into the MediVet business to advance its position in the regenerative medicine market for animals. The
business will continue to require further investment in both these areas and the new MediVet management team is
committed to doing so. MLA has taken this decision so that the Board and management can focus entirely on the further
growth and development of its successful Human Healthcare business.
Medical Australia’s Chief Executive Officer, Mr Darryl Ellis, said: “The divestment of MediVet now allows us to fully focus on
growing and developing the Human Healthcare business, upon which the Company was founded.”
“The savings that this divestment will deliver will provide MLA with the financial flexibility to fast track our strategy to expand
sales, supply and distribution agreements in the Human Healthcare business. The completion of this transaction will see the
Company return to trading that will be profitable and cash flow positive.”
– ENDS –
For more information contact:
Darryl Ellis
Chief Executive Officer

-------------

Finally... the truth is out: MediVet -longtime RGS Animal Health competitor- is worth near to nothing: $52K

Unlike RGS, MediVet has never been able to publish rigorous evidence of efficacy for its treatments.

How will RGS Animal Health leverage this in the market - especially with equine veterinarians, is going to be interesting.